Rhône-Poulenc Rorer Inc. regulatory update

RPR filed for Canadian marketing approval of Rilutek (riluzole) to treat amyotrophic lateral sclerosis (ALS). The Collegeville, Penn., company has filed for marketing approval of the drug in both Eur...